CD Genomics

Executive Summary

CD Genomics is a US-based genomics services company established in 2004, offering a comprehensive suite of sequencing, genotyping, and bioinformatics solutions to academic and industrial clients. The company leverages advanced platforms including next-generation sequencing (NGS), long-read technologies from PacBio and Oxford Nanopore, and multi-omics analysis to support research in agriculture, drug development, inherited diseases, microbiology, and oncology. With over two decades of experience, CD Genomics has positioned itself as a reliable partner for complex genomic projects, emphasizing data quality and turnaround time. The company operates in the competitive genomics services market, differentiated by its broad technology portfolio and focus on customized solutions. Despite being a private entity with limited public financial disclosures, its long-standing presence and diverse client base suggest stable operations and potential for steady growth.

Upcoming Catalysts (preview)

• Q3 2026Launch of Single-Cell Sequencing Service75% success
• Q2 2026Strategic Partnership with Major Pharmaceutical Company60% success
• TBDExpansion of Bioinformatics Platform with AI Integration80% success